Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 14/20 | 0.43 |
| ▸ | XIAP | P98170 | 11/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BIRC7 | Q96CA5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439205 | 0.90 | XIAP (0.45) | BIRC2XIAPCASP9BIRC3MEN1 | |
| SCHEMBL896287 | 0.90 | XIAP (0.43) | BIRC2XIAPCASP9BIRC3MEN1 | |
| SCHEMBL896286 | 0.90 | XIAP (0.43) | BIRC2XIAPCASP9BIRC3MEN1 | |
| SCHEMBL895868 | 0.89 | XIAP (0.54) | BIRC2XIAPBIRC3 | |
| SCHEMBL10081737 | 0.89 | XIAP (0.54) | BIRC2XIAPBIRC3 | |
| SCHEMBL10066053 | 0.88 | KCNH2 (0.46) | BIRC2XIAPCASP9BIRC3 | |
| SCHEMBL13119037 | 0.87 | XIAP (0.45) | BIRC2XIAPBIRC3MEN1HTT | |
| SCHEMBL20151716 | 0.87 | XIAP (0.56) | BIRC2XIAPCASP9BIRC3 | |
| SCHEMBL10066054 | 0.86 | BIRC2 (0.45) | BIRC2XIAPCASP9BIRC3BIRC7 | |
| SCHEMBL10081736 | 0.86 | BIRC2 (0.44) | BIRC2XIAPCASP9BIRC3BIRC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281385-A1 | SMALL MOLECULE APOPTOSIS PROMOTERS | JOYANT PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8222291-B2 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120082640-A1 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120082640-A1 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-7807699-B2 | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807699-B2 | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080051389-A1 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051389-A1 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007136921-A2 | SMALL MOLECULE APOPTOSIS PROMOTERS | JOYANT PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281385-A1 | SMALL MOLECULE APOPTOSIS PROMOTERS | BID, BAD, BAX | BIRC2 11/4885XIAP 31/4885CASP9 30/4885 |
| US-20080051389-A1 | Small molecule apoptosis promoters | BID, BAD, BAX | BIRC2 11/4885XIAP 31/4885CASP9 30/4885 |
| US-20120082640-A1 | Small molecule apoptosis promoters | BID, BAD, BAX | BIRC2 11/4885XIAP 31/4885CASP9 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.